Amid an intense legal battle with Apple, Masimo CEO Joe Kiani has announced his resignation from the company. Masimo, known for its advanced technology in the healthcare sector, managed to temporarily ban the sale of the Apple Watch in the United States, citing infringement of patents related to the oxygen monitoring in blood
This situation caused a huge stir in the technology and health industry, and now there is the resignation of the leader who has been leading the company during this fight, with the Apple Watch as the protagonist.
Legal battle between Apple and Masimo
Masimo has announced the resignation of Joe Kiani and the appointment of Michelle Brennan as interim CEO. Brennan thanked the trust and reaffirmed his commitment to the company’s growth and innovation, ensuring that the management team will continue to work with employees to ensure uninterrupted service and support.
The company reiterated its commitment to its current plans, including evaluating alternatives for its consumer audio and health divisions. Although the exact reasons for Kiani’s resignation have not been revealed, his role in the dispute with Apple has been paramount. The now former CEO had accused Apple of “masking” the health features of the Apple Watch and appropriating Masimo’s intellectual property.
The conflict between Apple and Masimo revolves around the pulse oximetry technology of the Apple Watch, introduced in 2020 with the Apple Watch Series 6. In January 2023, a US court found that Apple infringed a Masimo patent related to this technology. In October, the International Trade Commission upheld the ruling, ending the ban on sales of the Apple Watch Series 9 and Ultra 2 in the US.
The Apple Watch is legal
Faced with this ban, Apple took measures to circumvent the block, agreeing to disable features pulse oximetry in Apple Watch models sold in the country. This allowed the company to continue marketing its products, albeit without one of the key features that sets them apart in the competitive smartwatch market.
Kiani’s resignation comes at a crucial time for Masimo. His leadership has been fundamental in the expansion of the company and in consolidating its position as a reference in the field of medical technology. However, the dispute with Apple has meant a important challenge both in legal terms as a public image. Kiani’s departure could mark the beginning of a new stage for Masimo, one in which the company will seek not only to resolve the dispute with Apple, but also to consolidate in other areas of the consumer market.
For now, the industry is closely watching how this transition will play out at Masimo and what impact it will have on the ongoing battle with Apple. With Michelle Brennan at the helm on an interim basis, the company will have to navigate turbulent waters as it continues to seek to maintain its leadership in medical innovation and its market position against giants like Apple.
